This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages without signing in

Valsartan Anti-hypertensive Long-term Use Evaluation (VALUE)

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • Valsartan Anti-hypertensive Long-term Use Evaluation (VALUE) outcome trial to compare a angiotensin II receptor blocker (ARB), valsartan, with a third-generation calcium channel blocker (CCB), amlodipine, in a general hypertensive population at high cardiovascular risk
    • participants were mainly previously treated (92%) patients with hypertension
      • randomisation to low-dose valsartan (80 mg) or amlodipine (5 mg)
        • this was followed titration of therapy at monthly inter-vals to achieve a target blood pressure < 140/90 mmHg i.e. to valsartan 160 mg or amlodipine 10 mg followed by introduction of diuretic (hydrochlorothiazide) and then free add-on therapy as necessary
        • 15,313 individuals were randomised at 942 sites in 31 countries, and average follow-up was 4.2 years
        • 90 patients were lost to follow-up
        • on entry to the study: average age of 67 years, BP 155/88 mmHg
          • nearly 50% had coronary heart disease
          • one third had diabetes
          • one third had hypercholesterolaemia
          • one quarter were smokers
          • about one in five had proteinuria
          • about one in five had left ventricular hypertrophy and/or cerebrovascular disease
          • one in eight had peripheral arterial disease
  • Results
    • average blood pressure, 138/79 mmHg, at the end of the study
      • blood pressure was reduced by around 15/10mmHg during the course of the study
    • blood pressure levels were significantly lower in the amlodipine-treated patients
      • initially differences were more than 4/2 mmHg in favour of amlodipine
      • beyond six months the advantage in favour of amlodipine more than 2 mmHg for systolic blood pressure and 1–2 mmHg for diastolic blood pressure
    • the incidence of the composite cardiac outcome did not differ between the groups (hazard ratio 1.03, 95% confidence intervals 0.94–1.14; p=0.94) - this is despite the inferior blood pressure control of valsartan in comparison to amlodipine
    • no significant differences between the treatments for stroke or all-cause mortality
    • incidence of new-onset diabetes was significantly lower in valsartan-treated patients (23% reduction; p<0.0001)
    • both treatments were well tolerated - however significantly fewer discontinued therapy due to adverse events in the valsartan group (p=0.045) and peripheral oedema was much more common in the amlodipine group (33% vs. 15%, p<0.0001)
    • admission to hospital for heart failure was significantly lower with valsartan treated group
    • reaching blood pressure control (systolic <140 mm Hg) by 6 months, independent of drug type, was associated with significant benefits for subsequent major outcomes; the blood pressure response after just 1 month of treatment predicted events and survival

Reference:

  1. Weber M et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004 Jun 19;363(9426):2049-51.
  2. Julius S et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004 Jun 19;363(9426):2022-31

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.